Jubilant Life US arm gets approval from USFDA for 4 drugs

By Admin
The U.S.-based subsidiary of Jubilant Life Sciences Ltd namely Jubilant Cadista Pharmaceuticals., Inc has secured approvals from the U.S. Food and Drug...

The U.S.-based subsidiary of Jubilant Life Sciences Ltd namely Jubilant Cadista Pharmaceuticals., Inc has secured approvals from the U.S. Food and Drug Administration for four drugs. These include escitalpram tablets USP, 5mg, 10mg and 20mg, Olanzapine orally disintegrating tablet 5mg, 10mg, 15mg and 20 mg, Losartan potassium tablets USP, 25 mg, 50 mg and 100 mg and Losartan Potassium and  Hydrochlorothiazide tablets USP 50mg/12.5 mg, 100mg/12.5mg and 100mg/25mg.  

Mr. Shyam S Bhartia, Chairman and Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “The recent USFDA approvals for four solid dosage formulations reinforce our growth strategy through new product launches and further demonstrate our strength in vertical integration from in-house APIs to generics for cost competitive advantage.”

Escitalopram is used for acute treatment of generalized anxiety disorder and acute and maintenance treatment of major depressive disorders with its branded version,  LEXAPRO®.  

Another drug, Olanzapine ODT is a bioequivalent generic version of ZYPERXAZYDIS®.  It is used to treat schizophrenia and also for short-term treatment of acute manic or mixed episodes associated with Bipolar I disorder. 

Losartan Potassium is a potent, highly specific angiotensin receptor blocker.   Losartan Potassium and Hydrochlorothiazide tablets are a combination of ARB and a diuretic.  

Escitalopram and Olanzapine ODT would be manufactured in Jubilant’s dosage formulations facility at Roorkee, India. Jubilant Life Sciences is an integrated pharmaceutical and life sciences company. It is also the largest custom research and manufacturing services player.

Share
Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI